Insulin suppresses endothelial secretion of C-type natriuretic peptide, a novel endothelium-derived relaxing peptide

Toshio Igaki, Hiroshi Itoh, Shin Ichi Suga, Yasato Komatsu, Yoshihiro Ogawa, Kentaro Doi, Takaaki Yoshimasa, Kazuwa Nakao

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells (ECs) and acts as an endothelium-derived relaxing peptide. We further demonstrated the detection of the gene transcripts of CNP and atrial natriuretic peptide (ANP) B receptor, a specific receptor for CNP, in human blood vessels. We thus propose the existence of a vascular natriuretic peptide system (NPS). CNP secretion was also demonstrated to be stimulated by various growth factors and cytokines. To clarify the significance of vascular NPS in proliferative vascular complications associated with diabetes, hypertension, or atherosclerosis, in the present study we examined the effect of insulin on CNP secretion from cultured ECs. Insulin at a concentration in the physiological range (10-10-10-7 mol/l) potently suppressed CNP secretion, whereas insulin at the same concentration did not suppress endothelin (ET) secretion from EC. IGF-I had no significant effect on CNP secretion. Insulin, therefore, can be a potent inhibitor of CNP secretion through the activation of insulin receptor. Since CNP has been shown to be a potent inhibitor of vascular smooth muscle cell proliferation, the present study suggests the possibility that attenuated activity of vascular NPS is associated with hyperinsulinemia, which might result in proliferative vascular lesions.

Original languageEnglish
JournalDiabetes
Volume45
Issue number3 SUPPL.
Publication statusPublished - Dec 1 1996

Fingerprint

C-Type Natriuretic Peptide
Endothelium
Insulin
Peptides
Blood Vessels
Natriuretic Peptides
Endothelial Cells
Atrial Natriuretic Factor Receptors
Endothelins
Insulin Receptor
Hyperinsulinism
Insulin-Like Growth Factor I
Vascular Smooth Muscle
Smooth Muscle Myocytes
Cultured Cells
Atherosclerosis
Intercellular Signaling Peptides and Proteins
Cell Proliferation
Cytokines
Hypertension

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Igaki, T., Itoh, H., Suga, S. I., Komatsu, Y., Ogawa, Y., Doi, K., ... Nakao, K. (1996). Insulin suppresses endothelial secretion of C-type natriuretic peptide, a novel endothelium-derived relaxing peptide. Diabetes, 45(3 SUPPL.).

Insulin suppresses endothelial secretion of C-type natriuretic peptide, a novel endothelium-derived relaxing peptide. / Igaki, Toshio; Itoh, Hiroshi; Suga, Shin Ichi; Komatsu, Yasato; Ogawa, Yoshihiro; Doi, Kentaro; Yoshimasa, Takaaki; Nakao, Kazuwa.

In: Diabetes, Vol. 45, No. 3 SUPPL., 01.12.1996.

Research output: Contribution to journalArticle

Igaki, T, Itoh, H, Suga, SI, Komatsu, Y, Ogawa, Y, Doi, K, Yoshimasa, T & Nakao, K 1996, 'Insulin suppresses endothelial secretion of C-type natriuretic peptide, a novel endothelium-derived relaxing peptide', Diabetes, vol. 45, no. 3 SUPPL..
Igaki, Toshio ; Itoh, Hiroshi ; Suga, Shin Ichi ; Komatsu, Yasato ; Ogawa, Yoshihiro ; Doi, Kentaro ; Yoshimasa, Takaaki ; Nakao, Kazuwa. / Insulin suppresses endothelial secretion of C-type natriuretic peptide, a novel endothelium-derived relaxing peptide. In: Diabetes. 1996 ; Vol. 45, No. 3 SUPPL.
@article{8d0fe069a1e94c13b9e9c06c424da1c5,
title = "Insulin suppresses endothelial secretion of C-type natriuretic peptide, a novel endothelium-derived relaxing peptide",
abstract = "We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells (ECs) and acts as an endothelium-derived relaxing peptide. We further demonstrated the detection of the gene transcripts of CNP and atrial natriuretic peptide (ANP) B receptor, a specific receptor for CNP, in human blood vessels. We thus propose the existence of a vascular natriuretic peptide system (NPS). CNP secretion was also demonstrated to be stimulated by various growth factors and cytokines. To clarify the significance of vascular NPS in proliferative vascular complications associated with diabetes, hypertension, or atherosclerosis, in the present study we examined the effect of insulin on CNP secretion from cultured ECs. Insulin at a concentration in the physiological range (10-10-10-7 mol/l) potently suppressed CNP secretion, whereas insulin at the same concentration did not suppress endothelin (ET) secretion from EC. IGF-I had no significant effect on CNP secretion. Insulin, therefore, can be a potent inhibitor of CNP secretion through the activation of insulin receptor. Since CNP has been shown to be a potent inhibitor of vascular smooth muscle cell proliferation, the present study suggests the possibility that attenuated activity of vascular NPS is associated with hyperinsulinemia, which might result in proliferative vascular lesions.",
author = "Toshio Igaki and Hiroshi Itoh and Suga, {Shin Ichi} and Yasato Komatsu and Yoshihiro Ogawa and Kentaro Doi and Takaaki Yoshimasa and Kazuwa Nakao",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "45",
journal = "Diabetes",
issn = "0012-1797",
publisher = "医学出版",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Insulin suppresses endothelial secretion of C-type natriuretic peptide, a novel endothelium-derived relaxing peptide

AU - Igaki, Toshio

AU - Itoh, Hiroshi

AU - Suga, Shin Ichi

AU - Komatsu, Yasato

AU - Ogawa, Yoshihiro

AU - Doi, Kentaro

AU - Yoshimasa, Takaaki

AU - Nakao, Kazuwa

PY - 1996/12/1

Y1 - 1996/12/1

N2 - We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells (ECs) and acts as an endothelium-derived relaxing peptide. We further demonstrated the detection of the gene transcripts of CNP and atrial natriuretic peptide (ANP) B receptor, a specific receptor for CNP, in human blood vessels. We thus propose the existence of a vascular natriuretic peptide system (NPS). CNP secretion was also demonstrated to be stimulated by various growth factors and cytokines. To clarify the significance of vascular NPS in proliferative vascular complications associated with diabetes, hypertension, or atherosclerosis, in the present study we examined the effect of insulin on CNP secretion from cultured ECs. Insulin at a concentration in the physiological range (10-10-10-7 mol/l) potently suppressed CNP secretion, whereas insulin at the same concentration did not suppress endothelin (ET) secretion from EC. IGF-I had no significant effect on CNP secretion. Insulin, therefore, can be a potent inhibitor of CNP secretion through the activation of insulin receptor. Since CNP has been shown to be a potent inhibitor of vascular smooth muscle cell proliferation, the present study suggests the possibility that attenuated activity of vascular NPS is associated with hyperinsulinemia, which might result in proliferative vascular lesions.

AB - We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells (ECs) and acts as an endothelium-derived relaxing peptide. We further demonstrated the detection of the gene transcripts of CNP and atrial natriuretic peptide (ANP) B receptor, a specific receptor for CNP, in human blood vessels. We thus propose the existence of a vascular natriuretic peptide system (NPS). CNP secretion was also demonstrated to be stimulated by various growth factors and cytokines. To clarify the significance of vascular NPS in proliferative vascular complications associated with diabetes, hypertension, or atherosclerosis, in the present study we examined the effect of insulin on CNP secretion from cultured ECs. Insulin at a concentration in the physiological range (10-10-10-7 mol/l) potently suppressed CNP secretion, whereas insulin at the same concentration did not suppress endothelin (ET) secretion from EC. IGF-I had no significant effect on CNP secretion. Insulin, therefore, can be a potent inhibitor of CNP secretion through the activation of insulin receptor. Since CNP has been shown to be a potent inhibitor of vascular smooth muscle cell proliferation, the present study suggests the possibility that attenuated activity of vascular NPS is associated with hyperinsulinemia, which might result in proliferative vascular lesions.

UR - http://www.scopus.com/inward/record.url?scp=0029883049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029883049&partnerID=8YFLogxK

M3 - Article

C2 - 8674895

AN - SCOPUS:0029883049

VL - 45

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 3 SUPPL.

ER -